Safety and Clinical Performance of a Biological Matrix Used in Abdominal Wall Reconstruction (PMCF_AWR)

October 19, 2023 updated by: Meccellis Biotech

Safety and Clinical Performance of a Non-cross-linked Porcine Acellular Dermal Matrix Used in Abdominal Wall Reconstruction: an Observational Prospective Study.

The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS membrane used in abdominal wall reconstruction including, but not limited to, ventral hernia repair and stoma closure, and to identify emerging risks in comparison to the clinical data related to other types of fixation material.

The present study will be a prospective multicentric non-randomized and noncontrolled trial involving 112 patients followed for 24 months. The study will be conducted in France in 3 investigational centres.

Study Overview

Detailed Description

The study will be prospective, multicentric, single-arm, observational (non-interventional) to evaluate the safety and performance of the CELLIS membrane used in abdominal wall reconstruction including, but not limited to, ventral hernia repair and stoma closure.

All evaluations will be performed and products used according to the usual practice, without additional or unusual diagnostic, treatment and monitoring procedure.

The study will be conducted in France in 3 investigational centres including 112 patients scheduled for an abdominal wall reconstruction.

Each patient will participate in one assessment period including a preoperative visit, followed by the day of surgical procedure and a hospitalization period.

Patients will return for ambulatory visits on day 30 (+/- 7 days), on month 3 (+/- 2 weeks), on month 12 (+/- 2 weeks) and on month 24 (+/-2 weeks) post-surgery.

CELLIS will be implanted by open technique following standard techniques. The membrane can be used in bridged or reinforced repairs. Mesh placement can include inlay (bridging), underlay intraperitoneal, sublay (retrorectus/retromuscular) positions.

Study Type

Observational

Enrollment (Estimated)

112

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Caen, France
        • Recruiting
        • CHU Caen Normandie, Service de Chirurgie Digestive
        • Contact:
          • Gil LEBRETON, MD
        • Principal Investigator:
          • Gil Lebreton, MD
      • La Rochelle, France
        • Recruiting
        • Groupe Hospitalier La Rochelle - Re - Aunis
        • Contact:
          • Hélène GIBELIN, MD
        • Principal Investigator:
          • Hélène GIBELIN, MD
      • Montpellier, France
        • Recruiting
        • CHU Montpellier, Hôpital Saint-Eloi, Pôle digestif, Service de Chirurgie Digestive B et Transplantation
        • Contact:
          • Hassan BOUYABRINE, MD
        • Principal Investigator:
          • Hassan BOUYABRINE, MD
      • Nantes, France, 44093
        • Recruiting
        • CHU Nantes Hôtel Dieu
        • Contact:
          • Claire BLANCHARD-LOUIS, MD
        • Principal Investigator:
          • Claire BLANCHARD-LOUIS, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult with an indication of abdominal wall reconstruction including, but not limited to, ventral hernia repair and stoma closure.

Description

Inclusion Criteria:

  • Patient aged ≥18 years,
  • Patient with an indication of abdominal wall reconstruction including, but not limited to, ventral hernia repair and stoma closure,
  • Patient being informed of its participation to the study and of the follow-up visits, and having no objection to the clinical data collection and medical file access,
  • Patient being informed of the porcine origin of the device in advance of the procedure.

Exclusion Criteria:

  • Patient with known hypersensitivity to porcine materials,
  • Patient who is pregnant,
  • Patient having refused to participate to the study,
  • Patient refusing to return for the follow-up visits.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of adverse events including reoperation and removal of the mesh. The main complications of interest are Surgical Site Occurrence (SSO) including Surgical Site Infection (SSI).
Time Frame: From the surgical procedure throughout the entire 24-month follow-up period
Percentage
From the surgical procedure throughout the entire 24-month follow-up period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of recurrence/incisional hernia evaluated by clinical examination and/or CT-scan
Time Frame: Throughout the study until end of the 24-month follow-up period
Percentage
Throughout the study until end of the 24-month follow-up period
Rate of recurrence/incisional hernia requiring reoperation
Time Frame: Throughout the study until end of the 24-month follow-up period
Percentage
Throughout the study until end of the 24-month follow-up period
Rate of abdominal wall laxity
Time Frame: Throughout the study until end of the 24-month follow-up period
Percentage
Throughout the study until end of the 24-month follow-up period
Description of device deficiency: inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance. Device deficiencies include malfunctions, use errors, and inadequate labelling.
Time Frame: During the surgical procedure
Summarized and listed
During the surgical procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hassan BOUYABRINE, MD, CHU Montpellier, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 4, 2020

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 1, 2026

Study Registration Dates

First Submitted

October 2, 2020

First Submitted That Met QC Criteria

October 2, 2020

First Posted (Actual)

October 8, 2020

Study Record Updates

Last Update Posted (Actual)

October 23, 2023

Last Update Submitted That Met QC Criteria

October 19, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • AWR_01_CIP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Abdominal Hernia

Clinical Trials on CELLIS (Porcine Acellular Dermal Matrix, PADM)

3
Subscribe